180 Life Sciences files provisional patent on CBD with GLP-1 agonist combination

180 Life Sciences announced the filing of a provisional patent describing the novel combination of CBD, or an analog thereof, with glucagon related peptide-1 agonists to address the problem of obesity and weight management. Co-administration of Cannabidiol, a known appetite suppressant and antiemetic, might be expected both to limit the deleterious side effects and lower the effective dosage of the GLP-1 agonists. CBD has been shown to reduce inflammation and stimulate satiety, but establishing the details of the mode of action has been hampered by CBD binding over 50 different biological receptors. Consequently, we believe the scientific community has assumed the clinical benefits arise from a summation of weak stimulations of a spectrum of molecular pathways, rather than a single, critical biological signal. However, the recent clinical success of GLP-1 agonists in stimulating satiety and resultant weight reduction in patients with type 2 diabetes led 180LS scientists to hypothesize that CBD and GLP-1 might stimulate a common therapeutic pathway. The dramatically different structures of the two drugs make binding a common receptor unlikely, but we speculate that the two compounds could stimulate a common neurological pathway between the gut and the brain. GLP-1 signals satiety to the brain through stimulation of specific GLP-1 receptors expressed on the afferent arm of the vagus nerve. Scientists at 180 Life Sciences plan to collaborate with neurological experts to investigate whether cannabidiol stimulates satiety through a neural pathway involving the vagus nerve. Negotiations are currently underway with third party scientists for a research collaboration to design and execute testing of our theory as described following, of which there can be no assurance. This research collaboration is designed to determine whether CBD and GLP-1 stimulate a common signal for satiety to the brain. If so, CBD may represent a significantly less expensive alternative with fewer side effects than GLP-1 agonists for weight reduction. 180LS has licensed patents, based on the work of the late Dr. Mechoulam, that describe novel synthetic CBD compounds which could induce appetite suppression and be therapeutic for obesity and weight management.